Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
Mucopolysaccharidosis iv
MeSH D009085 - mucopolysaccharidosis iv
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009083:
Mucopolysaccharidoses
0 Companies
0 Drugs
Success rate
D009085:
Mucopolysaccharidosis iv
1 Company
1 Drug
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
BioMarin Pharmaceutical
Elosulfase alfa
Vimizim
2014-02-14
$724.294 M
Q4/23-Q3/24
Clinical Trials
Historical Success Rate
Phase 1
50
%
1/2
Phase 2
50
%
1/2
Phase 3
75
%
3/4
Approved:
2
Overall Success rate:
19%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
BioMarin Pharmaceutical
Elosulfase alfa
,
Aspartame
,
Lcp
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use